StockMarketWire.com - Diagnostics group for kidney disease Renalytix AI said positive results of a clinical validation study had undergone peer-review and been accepted for publication in the American Society of Nephrology Journal, Kidney360.

The study provided details of the primary analysis and numerous sub-analyses, which demonstrate robust performance of the company's KidneyIntelX test in the two clinical contexts, it said.




At 9:07am: [LON:RENX] Renalytix Ai PLC share price was 0p at 530p



Story provided by StockMarketWire.com